NMT1 and prostate carcinoma: Another myristoyl-CoA analogue, B13, also known as D-NMAPPD, potently inhibited NMT1 enzymatic activity against prostate cancer cells.199 By competing with the myristoyl-CoA binding site of NMT1, B13 impaired the myristoylation of Src, leading to the blocking of relevant oncogenic signalling and thereby promoting the antitumour effect.